Capital Impact Advisors LLC Has $38.39 Million Stake in ResMed Inc. $RMD

Capital Impact Advisors LLC lifted its stake in shares of ResMed Inc. (NYSE:RMD) by 253.8% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 159,358 shares of the medical equipment provider’s stock after buying an additional 114,318 shares during the period. ResMed accounts for about 3.0% of Capital Impact Advisors LLC’s investment portfolio, making the stock its 15th biggest holding. Capital Impact Advisors LLC’s holdings in ResMed were worth $38,385,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. International Assets Investment Management LLC acquired a new stake in shares of ResMed during the 4th quarter worth approximately $25,000. ORG Partners LLC grew its position in ResMed by 181.6% in the 4th quarter. ORG Partners LLC now owns 107 shares of the medical equipment provider’s stock valued at $26,000 after purchasing an additional 69 shares during the period. Imprint Wealth LLC acquired a new stake in ResMed in the 3rd quarter valued at $26,000. WFA of San Diego LLC acquired a new stake in ResMed in the 2nd quarter valued at $26,000. Finally, Sunbelt Securities Inc. acquired a new stake in ResMed in the 3rd quarter valued at $31,000. Institutional investors and hedge funds own 54.98% of the company’s stock.

ResMed Price Performance

Shares of NYSE:RMD opened at $186.48 on Thursday. The company has a current ratio of 3.01, a quick ratio of 2.33 and a debt-to-equity ratio of 0.06. The stock’s fifty day simple moving average is $208.33 and its two-hundred day simple moving average is $233.92. ResMed Inc. has a 1-year low of $180.26 and a 1-year high of $293.81. The stock has a market cap of $27.05 billion, a PE ratio of 17.98, a price-to-earnings-growth ratio of 1.24 and a beta of 0.80.

ResMed (NYSE:RMD) last issued its quarterly earnings data on Thursday, April 30th. The medical equipment provider reported $2.86 earnings per share for the quarter, beating the consensus estimate of $2.79 by $0.07. ResMed had a return on equity of 25.35% and a net margin of 27.44%.The business had revenue of $1.43 billion for the quarter, compared to analysts’ expectations of $1.42 billion. During the same period last year, the business earned $2.37 EPS. The business’s revenue was up 10.8% on a year-over-year basis. As a group, analysts forecast that ResMed Inc. will post 11.13 EPS for the current fiscal year.

ResMed Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, June 18th. Shareholders of record on Thursday, May 14th will be paid a dividend of $0.60 per share. The ex-dividend date is Thursday, May 14th. This represents a $2.40 annualized dividend and a yield of 1.3%. ResMed’s dividend payout ratio (DPR) is 23.14%.

Insider Buying and Selling at ResMed

In other ResMed news, Director Peter C. Farrell sold 2,000 shares of the firm’s stock in a transaction on Wednesday, April 1st. The stock was sold at an average price of $225.00, for a total transaction of $450,000.00. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Michael J. Farrell sold 4,991 shares of the firm’s stock in a transaction on Monday, June 8th. The shares were sold at an average price of $193.96, for a total value of $968,054.36. Following the transaction, the chief executive officer owned 466,256 shares in the company, valued at approximately $90,435,013.76. This trade represents a 1.06% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 16,973 shares of company stock worth $3,580,754. Company insiders own 0.65% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently issued reports on RMD. KeyCorp reduced their price target on shares of ResMed from $302.00 to $290.00 and set an “overweight” rating for the company in a research report on Monday, April 27th. Wall Street Zen downgraded shares of ResMed from a “buy” rating to a “hold” rating in a research report on Saturday, March 14th. JPMorgan Chase & Co. began coverage on shares of ResMed in a research report on Wednesday, April 15th. They issued an “overweight” rating for the company. Wells Fargo & Company reduced their price target on shares of ResMed from $270.00 to $227.00 and set an “equal weight” rating for the company in a research report on Friday, May 1st. Finally, Morgan Stanley reissued an “equal weight” rating and issued a $230.00 price target (down from $286.00) on shares of ResMed in a research report on Wednesday. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat, ResMed presently has a consensus rating of “Moderate Buy” and an average price target of $273.00.

About ResMed

ResMed (NYSE: RMD) is a global medical device and cloud-connectivity company focused on improving outcomes for people with sleep-disordered breathing and chronic respiratory conditions. Founded in 1989, the company is headquartered in San Diego, California, and develops, manufactures and distributes a range of devices and software used by patients, clinicians and providers worldwide.

ResMed’s product portfolio centers on noninvasive ventilation and sleep therapy equipment, including continuous positive airway pressure (CPAP) and bilevel devices, masks and related accessories for the treatment of obstructive sleep apnea and other respiratory disorders.